AcelRx Pharmaceuticals


Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)

Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX) and AcelRx Pharmaceuticals (ACRX) look forward to important regulatory approval decisions this year. Could these catalysts give these small …

AcelRx (ACRX): Shoring up the Balance Sheet by Selling Stock Comes with a Price

Shares of drug maker AcelRx Pharmaceuticals (NASDAQ:ACRX) slumped on Thursday, falling 13% as of 10:34 a.m.

Antares Pharma Inc (ATRS) and AcelRx Pharmaceuticals Inc (ACRX) Fail to Meet FDA Threshold; Analysts Weigh In

The complete response letter: Antares and AcelRx have just gotten the kind of mail no one wants to receive.

H. C. Wainwright Dives in on AcelRx Pharmaceuticals (ACRX) Following Phase 3 SAP302 Results

Last week, AcelRx Pharmaceuticals (NASDAQ:ACRX) presented results from its Phase 3 SAP302 trial for its pipeline drug ARX-04, designed to treat patients suffering …

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, …

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Awarded Contract from Department of Defense to Advance ARX-04

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, …

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) …

Roth Capital Remains Neutral On Acelrx Pharmaceuticals Following 3Q14 Update

Roth Capital analyst Ed Arce is out with his second note this week on Acelrx Pharmaceuticals (NASDAQ:ACRX) maintaining a Neutral rating with a $6 price target, following …

Roth Capital Remains Neutral On Acelrx As CEO Richard King Steps Down

Roth Capital analyst Ed Arce reaffirmed a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a $6 price target, as the company announced that CEO Richard …

Roth Capital Reiterates Neutral On Acelrx Pharmaceuticals, $6 PT

In a research report issued today, Roth Capital analyst Ed Arce reiterated a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a price target …